- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04825964
Exercise Capacity, Physical Activity Levels in Patients With Hyperthyroid
Comparison of Exercise Capacity and Physical Activity Levels in Patients With Hyperthyroid and Healthy Controls
Study Overview
Status
Conditions
Detailed Description
Hyperthyroidism is a pathological disease in which the synthesis and secretion of thyroid hormones are increased by the thyroid gland. Thyroid hormone excess affects many systems. Common clinical symptoms are fatigue, palpitations, disturbed sleep, weight loss, heat intolerance, sweating, tremors, polydipsia, and anxiety. Common physical findings are tachycardia, extremity tremors and weight loss.
Thyroid hormone directly affects skeletal muscles. Increased thyroid hormone causes myopathy with a decrease in muscle strength and mass. Hyperthyroid myopathy can cause a decrease in exercise capacity. The main cause of exercise intolerance in individuals with hyperthyroidism is the change in energy metabolism. The number of studies investigating the exercise capacity in hyperthyroid patients is limited. Information support will be provided to the literature by evaluating the exercise capacity in patients with hyperthyroidism.
Physical activity is positively associated with changes in cardiovascular risk factors. Neuromuscular symptoms and exercise intolerance seen with thyroid hormone excess can lead people to an inactive life. Indirect calorimetry, the gold standard in energy expenditure, has been shown to be highly correlated with metabolic holter.There are no studies evaluating physical activity level with metabolic holter in individuals with hyperthyroidism. In this study, physical activity level will be evaluated by metabolic holter.
Patients with hyperthyroidism referred to the Cardiopulmonary Rehabilitation Unit of Gazi University Physiotherapy and Rehabilitation Department by the physicians of the Department of Endocrinology and Metabolism of the Department of Internal Diseases of Gazi University Faculty of Medicine will be included in the study. Patients and healthy individuals will be evaluated and the evaluation results will be compared. According to the sample size analysis 15 patients and 15 healthy individuals with similar demographic characteristics will be included the study. Patients and healthy individuals will be selected according to predetermined inclusion and exclusion criteria. Patients will be evaluated twice. The first evaluation will be made in the new diagnosis. The second evaluation will be made in the euthyroidism.The assessments will be completed in two days.
Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Çankaya
-
Ankara, Çankaya, Turkey, 06490
- Gazi University Facutly of Health Sciences Department of Physiotheraphy and Rehabilitation, Cardiopulmonary Rehabilitation Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria for patients group: Patients who are;
- Individuals diagnosed with hyperthyroidism by a physician
- Individuals between the ages of 18-70
Exclusion criteria for patients group: Patients who are;
- Use of drugs that affect the heart rate (except for short-term beta blockers given to relieve thyrotoxicosis symptoms)
- having problems that limit physical activity (orthopedic, neurological, psychological)
- having comorbidities such as uncontrolled hypertension, diabetes mellitus, heart failure or atrial fibrillation
- use of any medication that may affect thyroid function
- patients with acute infection during evaluation
- patients with uncontrolled hypertension, diabetes mellitus
Inclusion criteria for healthy group: Participants who are;
- being between ages of 18 and 70
- willing to participate to the study
Exclusion criteria for healthy group: Participants who are;
- having any diagnosis of chronic diseases
- having health problems such as cooperation
- having acute infection during evaluation
- being current smokers
- being ex-smokers (≥10 pack*years)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Patients
Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated at diagnosis and after 1-3 months.
|
Healthy Controls
Functional exercise capacity (6 minutes walk test and 6 minutes stepper test), physical activity level (multi-sensor activity monitor), respiratory functions (spirometer), respiratory muscle strength (mouth pressure measurement), peripheral muscle strength (dynamometer), respiratory muscle endurance (incremental threshold loading test), quality of life (The Thyroid-Related Quality of Life-ThyPRO), fatigue (Fatigue Severity Scale), depression-anxiety-stress (Depression Anxiety Stress Scale-42), quality of sleep (Pittsburgh Sleep Quality Index) and shortness of breath (Modified Medical Research Council (MMRC)) will be evaluated one time.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Exercise Capacity
Time Frame: First Day
|
Functional exercise capacity will be evaluated with 6-minutes walking test according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
The total distance they walked for 6 minutes in a 30-meter straight corridor will be recorded.
|
First Day
|
Functional Exercise Capacity
Time Frame: Second Day
|
Functional exercise capacity will be evaluated with 6-minutes Stepper Test according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.
The total number of steps will be recorded for 6 minutes.
|
Second Day
|
Physical activity (Total energy expenditure)
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Total energy expenditure (joule / day) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Physical activity time (min / day))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Physical activity time (min / day)will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Active energy expenditure (joule / day))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Active energy expenditure (joule / day) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Average metabolic equivalent (MET / day))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Average metabolic equivalent (MET / day) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Number of steps (steps / day))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Number of steps (steps / day) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Time spent lying down (min / day) days))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Time spent lying down (min / day) days) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Physical activity (Sleep time (min / day))
Time Frame: Second Day
|
Physical activity will be evaluated with the Multi sensor activity monitor (SenseWear®, Inc Pittsburgh, ABD).
The patient will wear the multisensor physical activity monitor over the triceps muscle of the non-dominant arm for 3 continuous days.
The patient will be informed about removing the device while taking a bath.
Sleep time (min / day) will be measured with the multi-sensor physical activity monitor.
The parameters measured over two days will be averaged and analyzed with the "SenseWear® 7.0 Software" program.
|
Second Day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Respiratory Muscle Strength
Time Frame: First Day
|
Maximal inspiratory (MIP) and maximal expiratory (MEP) pressures expressing respiratory muscle strength will be measured with a portable mouth pressure measuring device according to ATS and ERS criteria.
|
First Day
|
Peripheral Muscle Strength
Time Frame: First Day
|
Isometric peripheral muscle strength will be measured with a portable hand dynamometer (JTECH Commander, USA).
Measurements will be repeated on the shoulder abductors and knee extensors three times on the right and left.
|
First Day
|
Respiratory Muscle Endurance
Time Frame: Second Day
|
Respiratory muscle endurance will be assessed by the POWERbreathe Wellness (POWERbreathe, Inspiratory Muscle Training (IMT) Technologies Ltd., Birmingham, UK) device and the respiratory muscle endurance test at increased threshold load.
The test will be started with 20% of the maximal inspiratory pressure and the pressure will be increased to 40%, 60%, 80% and 100% every two minutes.
Patients will be asked to continue breathing through the device during the test.
During the test, the number of breaths delivered and the maximal time reached during each 2-minute period will be recorded.
If the individual cannot breathe 3 consecutive times, the test will be terminated by the physiotherapist.
The total duration of the test and the maximum pressure value at which it continues to breathe for at least 1 minute will be multiplied.
The value found will be recorded as the respiratory muscle endurance value.inspiratory
pressure with a 20% increment every 2 minutes.
|
Second Day
|
Disease Specific Quality of Life
Time Frame: First Day
|
Quality of life was evaluated with the Turkish version of the Quality of Life Scale (ThyPRO) in Thyroid Patients.
For each question, a five-point Likert type (0 = not at all, 1 = very little, 2 = a little, 3 = a little bit, 4 = a lot) was used.
Each subscale is scored differently.
High scores indicate a decreased quality of life.
|
First Day
|
Fatigue
Time Frame: First Day
|
Fatigue will be evaluated using Turkish version of Fatigue Severity Scale.
This questionnaire includes 9 items and score range for each item from 1 to 7 point (7-point Likert scale).
Fatigue Severity Scale score is calculates by deriving an arithmetic mean.
Cut-scores of over 4 are indicative of significant fatigue (higher scores show more severe fatigue)score range for each item from 1 to 7 point (7-point Likert scale).
|
First Day
|
Shortness of breath
Time Frame: First Day
|
The Modified Medical Research Council (MMRC) dyspnea scale will be used to determine the perception of dyspnea during activities of daily living. Dyspnea is graded as: zero (shortness of breath with strenuous exercise only); one (shortness of breath when rushing or walking up a slight uphill); two (because of shortness of breath they walk slower than people of the same age or have to stop to breathe while walking at their own pace); three (stops to breathe after walking 100 meters or after a few minutes); and four (too short of breath to leave the house or shortness of breath when getting dressed).daily living activities. |
First Day
|
Sleep Quality
Time Frame: First Day
|
Sleep quality will be evaluated by Turkish adaptation of Pittsburgh Sleep Quality Index (PSQI).
The scale includes 24 questions.
The questions included in the scoring consist of seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, use of sleeping pills, and daytime dysfunction.
Total PSQI score varies between 0-21.
A total score greater than five indicates "poor sleep quality".
|
First Day
|
Depression Anxiety Stress
Time Frame: First Day
|
Depression, Anxiety and Stress Scale (DASS) was evaluated with Turkish version.
The scale is a four-digit Likert type scale.
The total scores of the scale vary between 0 and 42 for each sub-dimension.
A high score indicates that the individual has that problem.
|
First Day
|
Pulmonary function (Forced vital capacity (FVC))
Time Frame: First Day
|
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society guidelines.
Forced vital capacity (FVC) will be measured.
|
First Day
|
Pulmonary function (Forced expiratory volume in the first second (FEV1))
Time Frame: First Day
|
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society guidelines.
Forced expiratory volume in the first second (FEV1) will be measured.
|
First Day
|
Pulmonary function (FEV1 / FVC)
Time Frame: First Day
|
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society guidelines.
FEV1 / FVC will be measured.
|
First Day
|
Pulmonary function (Flow rate 25-75% of forced expiratory volume (FEF 25-75%))
Time Frame: First Day
|
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society guidelines.
Flow rate 25-75% of forced expiratory volume (FEF 25-75%) will be measured.
|
First Day
|
Pulmonary function (Peak flow rate (PEF))
Time Frame: First Day
|
Pulmonary function will be evaluated using the spirometry, according to American Thoracic Society and European Respiratory Society guidelines.
Peak flow rate (PEF) will be measured.
|
First Day
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Fidan YILMAZ, Pt, Gazi University
- Principal Investigator: Afruz BABAYEVA, MD, Gazi University
- Principal Investigator: İlhan YETKİN, Prof. Dr., Gazi University
Publications and helpful links
General Publications
- Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N. Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism. Chest. 1996 Jan;109(1):57-61. doi: 10.1378/chest.109.1.57.
- Siafakas NM, Milona I, Salesiotou V, Filaditaki V, Tzanakis N, Bouros D. Respiratory muscle strength in hyperthyroidism before and after treatment. Am Rev Respir Dis. 1992 Oct;146(4):1025-9. doi: 10.1164/ajrccm/146.4.1025.
- Goswami R, Guleria R, Gupta AK, Gupta N, Marwaha RK, Pande JN, Kochupillai N. Prevalence of diaphragmatic muscle weakness and dyspnoea in Graves' disease and their reversibility with carbimazole therapy. Eur J Endocrinol. 2002 Sep;147(3):299-303. doi: 10.1530/eje.0.1470299.
- Kendrick AH, O'Reilly JF, Laszlo G. Lung function and exercise performance in hyperthyroidism before and after treatment. Q J Med. 1988 Aug;68(256):615-27.
- McAllister RM, Delp MD, Laughlin MH. Thyroid status and exercise tolerance. Cardiovascular and metabolic considerations. Sports Med. 1995 Sep;20(3):189-98. doi: 10.2165/00007256-199520030-00005.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Gazi University 25
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperthyroidism
-
Zhang BoActive, not recruitingHyperthyroidism/ThyrotoxicosisChina
-
Dong Jun LimRecruitingHyperthyroidism/ThyrotoxicosisKorea, Republic of
-
Universiti Kebangsaan Malaysia Medical CentreCompletedHyperthyroidism/ThyrotoxicosisMalaysia
-
Medical University of WarsawInstitute of Cardiology, Warsaw, PolandCompletedHyperthyroidism/Thyrotoxicosis | Hyperthyroidism; Goiter | Iodine Induced Thyrotoxicosis | Contrast Media Adverse Reaction | Thyrotoxicosis of Other Specified Origin
-
Rijnstate HospitalAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); ZonMw: The... and other collaboratorsRecruitingRadiofrequency Ablation | Thyroid Nodule, Toxic or With Hyperthyroidism | Autonomous Thyroid Function | Thyroid Nodule; Hyperthyroidism | Iodine Hyperthyroidism | Iodine Adverse ReactionNetherlands
-
University of BelgradeUnknownPregnancy Complicated by Hyperthyroidism | Hypothyroidism in PregnancySerbia
-
University of BelgradeCompletedPregnancy Complicated by Hyperthyroidism | Hypothyroidism in PregnancySerbia
-
Assistance Publique - Hôpitaux de ParisCompletedComplication of Hemodialysis | Hyperthyroidism Treated or Under ControlFrance
-
Rigshospitalet, DenmarkOdense University Hospital; Hvidovre University Hospital; Bispebjerg Hospital; Herlev... and other collaboratorsUnknownGraves' HyperthyroidismDenmark
-
Jesús María Villar del MoralCompletedHyperthyroidism, AutoimmuneSpain